Keyphrases
Ultrasound Imaging
100%
Tumor Model
100%
Antiangiogenic Therapy
100%
Early Responder
100%
Contrast-enhanced Ultrasound
100%
Bevacizumab
60%
Tumor
40%
Perfusion
40%
Bevacizumab Treatment
40%
Significant Benefit
20%
Vasculature
20%
Microbubbles
20%
Cancer Therapeutics
20%
Molecular Imaging
20%
Vascular Endothelial Growth Factor
20%
Pruning
20%
Blood Volume
20%
Treatment Initiation
20%
Vascular Endothelial Growth Factor Inhibition
20%
Targeted Microbubbles
20%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
20%
Effective Determination
20%
Prognostic Indicator
20%
Molecular Imaging Techniques
20%
Non-responders
20%
Tumor Subtype
20%
Non-invasive Ultrasound
20%
Xenograft Model
20%
Branching Vessels
20%
Lectin
20%
Ultrasound Approach
20%
Medicine and Dentistry
Bevacizumab
100%
Ultrasonography
100%
Antiangiogenic Therapy
100%
Tumor Model
100%
Contrast-Enhanced Ultrasound
80%
Neoplasm
60%
Molecular Imaging
40%
Vasculotropin
40%
Vascularity
20%
Malignant Neoplasm
20%
Vasculotropin Antibody
20%
Imaging Technique
20%
Lectin
20%
Xenograft
20%
Pharmacology, Toxicology and Pharmaceutical Science
Bevacizumab
100%
Antiangiogenic Therapy
100%
Tumor Model
100%
Neoplasm
60%
Vasculotropin
40%
Malignant Neoplasm
20%
Vasculotropin Antibody
20%
Lectin
20%
Immunology and Microbiology
Bevacizumab
100%
Molecular Imaging
40%
Perfusion
40%
Microbubble
40%
Vasculotropin
40%
Vascularization
20%
Lectin
20%
Xenograft
20%
Vasculotropin Antibody
20%
Biochemistry, Genetics and Molecular Biology
Bevacizumab
100%
Vascular Endothelial Growth Factor
60%
Perfusion
40%
Microbubble
40%
Vascularization
20%
Lectin
20%